文献速递类风湿关节炎

NORD-STAR试验48周患者报告结局:早期类风湿关节炎四种治疗策略比较

Certolizumab pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: 48-week patient-reported outcomes from the NORD-STAR trial.
PubMed 文献 · Lancet Rheumatol · 2026-01-01

NORD-STAR是一项开放标签随机对照试验,纳入812例早期未使用过DMARD的类风湿关节炎患者,随机分配至传统治疗、certolizumab pegol、abatacept或tocilizumab组。48周时所有组患者报告结局均显著改善,生物制剂组在疼痛、疲劳和SF-36躯体疼痛及生理功能方面改善略优于传统治疗组,但组间绝对差异普遍较小。

要点

  • 生物制剂组在疼痛、疲劳及SF-36生理功能方面改善略优于传统治疗组。
  • 疼痛改善超过MCID的比例:certolizumab pegol组76%,abatacept组79%,传统治疗组68%。
  • 所有治疗组48周患者报告结局均较基线有大幅且临床相关改善。

核心结论

  • 所有治疗组患者报告结局随时间显著改善,生物制剂在疼痛、疲劳和生理生活质量方面略优于传统治疗,但总体组间差异较小。

研究设计与样本

  • NORD-STAR为研究者发起的开放标签随机对照试验,在丹麦、芬兰、冰岛、挪威、瑞典和荷兰的29个风湿病中心进行。
  • 纳入新诊断的类风湿关节炎患者,年龄≥18岁,症状持续时间<24个月,未使用过DMARD,随机按1:1:1:1分配至传统治疗、certolizumab pegol、abatacept或tocilizumab组。
  • 2012年12月14日至2018年12月11日期间共812例患者入组随机,排除17例因行政原因未接受tocilizumab的患者后,意向性治疗人群为795例。

主要发现

  • 48周时生物制剂组在疼痛、疲劳、SF-36生理功能评分和躯体疼痛方面较传统治疗组改善更大。
  • 疼痛改善超过MCID的患者比例:certolizumab pegol联合甲氨蝶呤组155/203(76%),abatacept联合甲氨蝶呤组162/204(79%),传统治疗组136/200(68%),tocilizumab联合甲氨蝶呤组132/188(70%)。
  • 生物制剂组与传统治疗组之间的绝对差异除此之外普遍较小。

关键数值与推荐

  • 疼痛改善超过MCID的比例:certolizumab pegol组76%,abatacept组79%,tocilizumab组70%,传统治疗组68%。

临床怎么用

  • 早期类风湿关节炎应尽早治疗并有效控制疾病活动,无论选择何种治疗类型均可带来显著的患者报告获益。
  • 生物制剂可在疼痛、疲劳和生理生活质量方面带来略优于传统治疗的改善,但组间差异较小,临床决策需综合考虑。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pain, fatigue, and impaired health-related quality of life are common manifestations of rheumatoid arthritis. The aim of this study was to compare the effects of active conventional treatment with three different biological disease-modifying antirheumatic drugs (DMARDs) on patient-reported outcomes after 48 weeks, in patients with early rheumatoid arthritis using data from the NORD-STAR trial. METHODS: NORD-STAR was an investigator-initiated open-label randomised controlled trial done at 29 rheumatology centres across Denmark, Finland, Iceland, Norway, Sweden, and the Netherlands. Newly diagnosed patients aged 18 years or older, with rheumatoid arthritis (according to the 2010 American College of Rheumatology-European Allience of Associations for Rheumatology classification criteria for rheumatoid arthritis), symptom duration less than 24 months and who were naïve to DMARDs were randomly assigned (1:1:1:1) to receive active conventional treatment, certolizumab pegol, abatacept, or tocilizumab. The patient-reported outcomes assessed at baseline and weeks 4, 8, 12, 16, 24, 32, 40, and 48 included pain, patient's global assessment of disease activity, Health Assessment Questionnaire Disability Index, Fatigue, Short Form-36 (reflecting health-related quality of life, morning stiffness, and patient's acceptable symptom state). Linear mixed regression and logistic regression analyses were adjusted for sex, country, baseline patient-reported outcomes values, anti-citrullinated protein antibody status, and treatment group. Proportions of patients reporting improvements greater than or equal to the minimal clinically important difference (MCID) were assessed. There was lived experience involvement in the design and implementation of the study. This trial was registered with ClinicalTrials.gov, NCT01491815, and EudraCT, 2011-004720-35. FINDINGS: Between Dec 14, 2012, and Dec 11, 2018, 812 patients were enrolled and randomly assigned; after exclusion of 17 patients not receiving tocilizumab due to administrative issues, the intention-to-treat population consisted of 795 patients (200 [25%] received active conventional treatment, 203 [26%] received certolizumab pegol plus methotrexate, 204 [26%] received abatacept plus methotrexate, and 188 [24%] received tocilizumab plus methotrexate). 547 (69%) of 795 patients were female, 248 (31%) were male, the mean age was 54 years (SD 15). Between baseline and week 48 large and clinically relevant improvements in patient-reported outcomes were observed in all treatment groups. At 48 weeks the biological DMARD groups had larger improvements in pain, fatigue, physical component score, and bodily pain of SF-36 compared with the active conventional treatment group. For pain, improvement exceeding MCID was reported by 155 (76%) of 203 patients with certolizumab pegol plus methotrexate and 162 (79%) of 204 patients with abatacept plus methotrexate compared with 136 (68%) of 200 patients in the active conventional treatment group. In the group of patients with tocilizumab and methotrexate 132 (70%) of 188 patients reported pain improvement exceeding MCID. The absolute differences between the biological DMARD groups and the active conventional treatment group were otherwise generally marginal. INTERPRETATION: All treatment groups showed substantial improvements in patient-reported outcomes over time. Biological DMARDs produced somewhat greater gains in pain, fatigue, and physical quality of life measures than conventional treatments, though overall differences between groups were small. The results highlight that early treatment and effective disease control in rheumatoid arthritis lead to strong patient-reported benefits regardless of therapy type. FUNDING: Stockholm County Council, Swedish Medical Research Council, Swedish Rheumatism Association, Academy of Finland, Finska Läkaresällskapet, South-Eastern Health Region Norway, HUS Institutional grant, Icelandic Society for Rheumatology, Interregional grant from all health regions in Norway, NordForsk, Regionernes Medicinpulje, The Research Fund of University Hospital Reykjavik, UCB, Bristol Myers Squibb.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Lampa J, Nordström D, van Vollenhoven R, et al. Certolizumab pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: 48-week patient-reported outcomes from the NORD-STAR trial. Lancet Rheumatol. 2026. PMID: 41881637. doi:10.1016/S2665-9913(26)00007-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。